Veterinary Infectious Disease Therapeutics Market Size, Share and Growth Outlook 2026: By Product Category, By Pathogen Indication Type, By Target Animal Category, By Route of Administration, By End-Use Facility, Companies to 2034
The global Veterinary Infectious Disease Therapeutics Market size is forecast to increase from $3.79 Billion in 2026 to $7.44 Billion in 2034 at a CAGR of 8.8% between 2026 and 2034.
The Veterinary Infectious Disease Therapeutics market report provides detailed analysis and outlook of Veterinary Infectious Disease Therapeutics segments including By Product Category (Anti-infectives and Antibiotics, Veterinary Biologics and Vaccines, Antivirals and Antifungals, Parasiticides and Medicated Feed Additives), By Pathogen Indication Type (Bacterial Infectious Diseases, Viral Infectious Diseases, Parasitic and Fungal Zoonotic Diseases), By Target Animal Category (Companion Animals, Production / Livestock Animals ), By Route of Administration (Oral / Feed and Water Additives, Parenteral, Topical / External Applications), By End-Use Facility (Veterinary Hospitals and Specialty Care Centers, Independent Veterinary Clinics and Emergency Units, Animal Research Facilities and Commercial Livestock Farms) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Veterinary Infectious Disease Therapeutics Industry Overview
Advanced Vaccines, Biologics, and Disease Prevention Strategies Are Driving Veterinary Infectious Disease Therapeutics
The global veterinary infectious disease therapeutics industry is advancing as livestock producers, companion animal healthcare providers, and veterinary pharmaceutical companies strengthen preventive disease management through vaccines, monoclonal antibodies, and next-generation biologics. Rising concerns surrounding antimicrobial resistance, animal welfare, food security, and production efficiency are accelerating investment in preventive immunization, precision therapeutics, and advanced vaccine delivery technologies. Manufacturers are also integrating diagnostics, biomarkers, and biosecurity solutions to support comprehensive infectious disease control across both livestock and companion animal populations, reinforcing preventive veterinary medicine as a cornerstone of animal health management.
Vaccine Innovation and Automated Delivery Technologies Are Expanding Prevention
The industry is increasingly focused on proactive disease prevention through highly targeted vaccines and scalable immunization platforms. Boehringer Ingelheim introduced LENZELTA®, a bovine vaccine administered in a two-dose regimen during the dry-off period, providing up to six months of protection against Staphylococcus aureus and Escherichia coli, two major pathogens responsible for clinical mastitis in dairy cattle. Meanwhile, Merck Animal Health entered into an agreement to acquire TARGAN, integrating automated high-speed poultry vaccine delivery technologies that enhance early-life immunization, strengthen biosecurity, and improve disease prevention across commercial poultry operations. These developments highlight the industry's continued investment in efficient, preventive infectious disease management.
Biologics and Diagnostic Innovation Are Strengthening Animal Health Pipelines
Manufacturers are expanding infectious disease portfolios beyond conventional vaccines by incorporating biologics and advanced diagnostics. Zoetis reported significant pipeline progress following expanded regulatory approvals for its monoclonal antibody therapeutics across the European Union and Canada, while reaffirming investment in late-stage development of diagnostic biomarkers and vaccines targeting companion animal infectious diseases. By leveraging scientific advances originating in human medicine, veterinary pharmaceutical companies are accelerating development of precision therapeutics capable of improving disease prevention, diagnosis, and long-term animal health outcomes. Continued innovation in vaccines, biologics, and diagnostic technologies is strengthening the global veterinary infectious disease therapeutics landscape.
Veterinary Infectious Disease Therapeutics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Veterinary Infectious Disease Therapeutics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Zoetis Inc., Merck & Co., Inc, Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Ceva Sant? Animale, Virbac S.A., Vetoquinol S.A., Dechra Pharmaceuticals PLC, IDEXX Laboratories, Inc., Phibro Animal Health Corporation. The Veterinary Infectious Disease Therapeutics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Veterinary Infectious Disease Therapeutics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Veterinary Infectious Disease Therapeutics industry include- Zoetis Inc., Merck & Co., Inc, Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Ceva Sant? Animale, Virbac S.A., Vetoquinol S.A., Dechra Pharmaceuticals PLC, IDEXX Laboratories, Inc., Phibro Animal Health Corporation. The Veterinary Infectious Disease Therapeutics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Veterinary Infectious Disease Therapeutics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Veterinary Infectious Disease Therapeutics market remains one of the strongest-performing segments in the country.
The US Veterinary Infectious Disease Therapeutics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Veterinary Infectious Disease Therapeutics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Veterinary Infectious Disease Therapeutics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Veterinary Infectious Disease Therapeutics markets
Canada's strong Veterinary Infectious Disease Therapeutics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Veterinary Infectious Disease Therapeutics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Veterinary Infectious Disease Therapeutics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Veterinary Infectious Disease Therapeutics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Veterinary Infectious Disease Therapeutics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Veterinary Infectious Disease Therapeutics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Veterinary Infectious Disease Therapeutics market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Veterinary Infectious Disease Therapeutics sales through 2034
France Veterinary Infectious Disease Therapeutics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Veterinary Infectious Disease Therapeutics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Veterinary Infectious Disease Therapeutics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Veterinary Infectious Disease Therapeutics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Veterinary Infectious Disease Therapeutics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Veterinary Infectious Disease Therapeutics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Veterinary Infectious Disease Therapeutics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Veterinary Infectious Disease Therapeutics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Veterinary Infectious Disease Therapeutics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Veterinary Infectious Disease Therapeutics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Veterinary Infectious Disease Therapeutics Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Veterinary Infectious Disease Therapeutics Market Segmentation
By Product Category
Anti-infectives and Antibiotics
Veterinary Biologics and Vaccines
Antivirals and Antifungals
Parasiticides and Medicated Feed Additives
By Pathogen Indication Type
Bacterial Infectious Diseases
Viral Infectious Diseases
Parasitic and Fungal Zoonotic Diseases
By Target Animal Category
Companion Animals
Production / Livestock Animals
By Route of Administration
Oral / Feed and Water Additives
Parenteral
Topical / External Applications
By End-Use Facility
Veterinary Hospitals and Specialty Care Centers
Independent Veterinary Clinics and Emergency Units
Animal Research Facilities and Commercial Livestock Farms
Leading Companies in Veterinary Infectious Disease Therapeutics Industry (2026)
Zoetis Inc.
Merck & Co., Inc
Boehringer Ingelheim Animal Health
Elanco Animal Health Incorporated
Ceva Sant? Animale
Virbac S.A.
Vetoquinol S.A.
Dechra Pharmaceuticals PLC
IDEXX Laboratories, Inc.
Phibro Animal Health Corporation
Countries Included
The Veterinary Infectious Disease Therapeutics market report provides detailed analysis and outlook of Veterinary Infectious Disease Therapeutics segments including By Product Category (Anti-infectives and Antibiotics, Veterinary Biologics and Vaccines, Antivirals and Antifungals, Parasiticides and Medicated Feed Additives), By Pathogen Indication Type (Bacterial Infectious Diseases, Viral Infectious Diseases, Parasitic and Fungal Zoonotic Diseases), By Target Animal Category (Companion Animals, Production / Livestock Animals ), By Route of Administration (Oral / Feed and Water Additives, Parenteral, Topical / External Applications), By End-Use Facility (Veterinary Hospitals and Specialty Care Centers, Independent Veterinary Clinics and Emergency Units, Animal Research Facilities and Commercial Livestock Farms) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Veterinary Infectious Disease Therapeutics Industry Overview
Advanced Vaccines, Biologics, and Disease Prevention Strategies Are Driving Veterinary Infectious Disease Therapeutics
The global veterinary infectious disease therapeutics industry is advancing as livestock producers, companion animal healthcare providers, and veterinary pharmaceutical companies strengthen preventive disease management through vaccines, monoclonal antibodies, and next-generation biologics. Rising concerns surrounding antimicrobial resistance, animal welfare, food security, and production efficiency are accelerating investment in preventive immunization, precision therapeutics, and advanced vaccine delivery technologies. Manufacturers are also integrating diagnostics, biomarkers, and biosecurity solutions to support comprehensive infectious disease control across both livestock and companion animal populations, reinforcing preventive veterinary medicine as a cornerstone of animal health management.
Vaccine Innovation and Automated Delivery Technologies Are Expanding Prevention
The industry is increasingly focused on proactive disease prevention through highly targeted vaccines and scalable immunization platforms. Boehringer Ingelheim introduced LENZELTA®, a bovine vaccine administered in a two-dose regimen during the dry-off period, providing up to six months of protection against Staphylococcus aureus and Escherichia coli, two major pathogens responsible for clinical mastitis in dairy cattle. Meanwhile, Merck Animal Health entered into an agreement to acquire TARGAN, integrating automated high-speed poultry vaccine delivery technologies that enhance early-life immunization, strengthen biosecurity, and improve disease prevention across commercial poultry operations. These developments highlight the industry's continued investment in efficient, preventive infectious disease management.
Biologics and Diagnostic Innovation Are Strengthening Animal Health Pipelines
Manufacturers are expanding infectious disease portfolios beyond conventional vaccines by incorporating biologics and advanced diagnostics. Zoetis reported significant pipeline progress following expanded regulatory approvals for its monoclonal antibody therapeutics across the European Union and Canada, while reaffirming investment in late-stage development of diagnostic biomarkers and vaccines targeting companion animal infectious diseases. By leveraging scientific advances originating in human medicine, veterinary pharmaceutical companies are accelerating development of precision therapeutics capable of improving disease prevention, diagnosis, and long-term animal health outcomes. Continued innovation in vaccines, biologics, and diagnostic technologies is strengthening the global veterinary infectious disease therapeutics landscape.
Veterinary Infectious Disease Therapeutics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Veterinary Infectious Disease Therapeutics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Zoetis Inc., Merck & Co., Inc, Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Ceva Sant? Animale, Virbac S.A., Vetoquinol S.A., Dechra Pharmaceuticals PLC, IDEXX Laboratories, Inc., Phibro Animal Health Corporation. The Veterinary Infectious Disease Therapeutics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Veterinary Infectious Disease Therapeutics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Veterinary Infectious Disease Therapeutics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Veterinary Infectious Disease Therapeutics companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Veterinary Infectious Disease Therapeutics markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Veterinary Infectious Disease Therapeutics industry include- Zoetis Inc., Merck & Co., Inc, Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Ceva Sant? Animale, Virbac S.A., Vetoquinol S.A., Dechra Pharmaceuticals PLC, IDEXX Laboratories, Inc., Phibro Animal Health Corporation. The Veterinary Infectious Disease Therapeutics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Veterinary Infectious Disease Therapeutics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Veterinary Infectious Disease Therapeutics market remains one of the strongest-performing segments in the country.
The US Veterinary Infectious Disease Therapeutics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Veterinary Infectious Disease Therapeutics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Veterinary Infectious Disease Therapeutics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Veterinary Infectious Disease Therapeutics markets
Canada's strong Veterinary Infectious Disease Therapeutics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Veterinary Infectious Disease Therapeutics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Veterinary Infectious Disease Therapeutics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Veterinary Infectious Disease Therapeutics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Veterinary Infectious Disease Therapeutics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Veterinary Infectious Disease Therapeutics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Veterinary Infectious Disease Therapeutics market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Veterinary Infectious Disease Therapeutics sales through 2034
France Veterinary Infectious Disease Therapeutics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Veterinary Infectious Disease Therapeutics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Veterinary Infectious Disease Therapeutics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Veterinary Infectious Disease Therapeutics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Veterinary Infectious Disease Therapeutics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Veterinary Infectious Disease Therapeutics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Veterinary Infectious Disease Therapeutics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Veterinary Infectious Disease Therapeutics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Veterinary Infectious Disease Therapeutics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Veterinary Infectious Disease Therapeutics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Veterinary Infectious Disease Therapeutics Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Veterinary Infectious Disease Therapeutics Market Segmentation
By Product Category
Anti-infectives and Antibiotics
Veterinary Biologics and Vaccines
Antivirals and Antifungals
Parasiticides and Medicated Feed Additives
By Pathogen Indication Type
Bacterial Infectious Diseases
Viral Infectious Diseases
Parasitic and Fungal Zoonotic Diseases
By Target Animal Category
Companion Animals
Production / Livestock Animals
By Route of Administration
Oral / Feed and Water Additives
Parenteral
Topical / External Applications
By End-Use Facility
Veterinary Hospitals and Specialty Care Centers
Independent Veterinary Clinics and Emergency Units
Animal Research Facilities and Commercial Livestock Farms
Leading Companies in Veterinary Infectious Disease Therapeutics Industry (2026)
Zoetis Inc.
Merck & Co., Inc
Boehringer Ingelheim Animal Health
Elanco Animal Health Incorporated
Ceva Sant? Animale
Virbac S.A.
Vetoquinol S.A.
Dechra Pharmaceuticals PLC
IDEXX Laboratories, Inc.
Phibro Animal Health Corporation
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Veterinary Infectious Disease Therapeutics Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Veterinary Infectious Disease Therapeutics Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Veterinary Infectious Disease Therapeutics Markets in 2026
3.2. Global Historic and Forecast Veterinary Infectious Disease Therapeutics Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Veterinary Infectious Disease Therapeutics Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Veterinary Infectious Disease Therapeutics Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Veterinary Infectious Disease Therapeutics Value Chain
CHAPTER 4- VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Veterinary Infectious Disease Therapeutics Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product Category
Anti-infectives and Antibiotics
Veterinary Biologics and Vaccines
Antivirals and Antifungals
Parasiticides and Medicated Feed Additives
By Pathogen Indication Type
Bacterial Infectious Diseases
Viral Infectious Diseases
Parasitic and Fungal Zoonotic Diseases
By Target Animal Category
Companion Animals
Production / Livestock Animals
By Route of Administration
Oral / Feed and Water Additives
Parenteral
Topical / External Applications
By End-Use Facility
Veterinary Hospitals and Specialty Care Centers
Independent Veterinary Clinics and Emergency Units
Animal Research Facilities and Commercial Livestock Farms
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Veterinary Infectious Disease Therapeutics Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Veterinary Infectious Disease Therapeutics Market Trends and Growth Opportunities to 2034
7.5. North America Veterinary Infectious Disease Therapeutics Market Size Outlook by Type
7.6. North America Veterinary Infectious Disease Therapeutics Market Size Outlook by Application
7.7. North America Veterinary Infectious Disease Therapeutics Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Veterinary Infectious Disease Therapeutics Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Veterinary Infectious Disease Therapeutics Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Veterinary Infectious Disease Therapeutics Companies
CHAPTER 8- EUROPE VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Veterinary Infectious Disease Therapeutics Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Veterinary Infectious Disease Therapeutics Market Trends and Growth Opportunities to 2034
8.5. Europe Veterinary Infectious Disease Therapeutics Market Size Outlook by Type
8.6. Europe Veterinary Infectious Disease Therapeutics Market Size Outlook by Application
8.7. Europe Veterinary Infectious Disease Therapeutics Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Veterinary Infectious Disease Therapeutics Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Veterinary Infectious Disease Therapeutics Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Veterinary Infectious Disease Therapeutics Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Veterinary Infectious Disease Therapeutics Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Veterinary Infectious Disease Therapeutics Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Veterinary Infectious Disease Therapeutics Companies
CHAPTER 9- ASIA PACIFIC VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Veterinary Infectious Disease Therapeutics Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Veterinary Infectious Disease Therapeutics Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Veterinary Infectious Disease Therapeutics Market Size Outlook by Type
9.6. Asia Pacific Veterinary Infectious Disease Therapeutics Market Size Outlook by Application
9.7. Asia Pacific Veterinary Infectious Disease Therapeutics Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Veterinary Infectious Disease Therapeutics Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Veterinary Infectious Disease Therapeutics Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Veterinary Infectious Disease Therapeutics Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Veterinary Infectious Disease Therapeutics Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Veterinary Infectious Disease Therapeutics Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Veterinary Infectious Disease Therapeutics Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Veterinary Infectious Disease Therapeutics Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Veterinary Infectious Disease Therapeutics Market Trends and Growth Opportunities to 2034
10.5. South and Central America Veterinary Infectious Disease Therapeutics Market Size Outlook by Type
10.6. South and Central America Veterinary Infectious Disease Therapeutics Market Size Outlook by Application
10.7. South and Central America Veterinary Infectious Disease Therapeutics Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Veterinary Infectious Disease Therapeutics Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Veterinary Infectious Disease Therapeutics Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Veterinary Infectious Disease Therapeutics Companies
CHAPTER 11- MIDDLE EAST AND AFRICA VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Veterinary Infectious Disease Therapeutics Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Veterinary Infectious Disease Therapeutics Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Veterinary Infectious Disease Therapeutics Market Size Outlook by Type
11.6. Middle East and Africa Veterinary Infectious Disease Therapeutics Market Size Outlook by Application
11.7. Middle East and Africa Veterinary Infectious Disease Therapeutics Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Veterinary Infectious Disease Therapeutics Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Veterinary Infectious Disease Therapeutics Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Veterinary Infectious Disease Therapeutics Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Veterinary Infectious Disease Therapeutics Industry
Zoetis Inc.
Merck & Co., Inc
Boehringer Ingelheim Animal Health
Elanco Animal Health Incorporated
Ceva Sant? Animale
Virbac S.A.
Vetoquinol S.A.
Dechra Pharmaceuticals PLC
IDEXX Laboratories, Inc.
Phibro Animal Health Corporation
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Veterinary Infectious Disease Therapeutics Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Veterinary Infectious Disease Therapeutics Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Veterinary Infectious Disease Therapeutics Markets in 2026
3.2. Global Historic and Forecast Veterinary Infectious Disease Therapeutics Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Veterinary Infectious Disease Therapeutics Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Veterinary Infectious Disease Therapeutics Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Veterinary Infectious Disease Therapeutics Value Chain
CHAPTER 4- VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Veterinary Infectious Disease Therapeutics Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product Category
Anti-infectives and Antibiotics
Veterinary Biologics and Vaccines
Antivirals and Antifungals
Parasiticides and Medicated Feed Additives
By Pathogen Indication Type
Bacterial Infectious Diseases
Viral Infectious Diseases
Parasitic and Fungal Zoonotic Diseases
By Target Animal Category
Companion Animals
Production / Livestock Animals
By Route of Administration
Oral / Feed and Water Additives
Parenteral
Topical / External Applications
By End-Use Facility
Veterinary Hospitals and Specialty Care Centers
Independent Veterinary Clinics and Emergency Units
Animal Research Facilities and Commercial Livestock Farms
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Veterinary Infectious Disease Therapeutics Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Veterinary Infectious Disease Therapeutics Market Trends and Growth Opportunities to 2034
7.5. North America Veterinary Infectious Disease Therapeutics Market Size Outlook by Type
7.6. North America Veterinary Infectious Disease Therapeutics Market Size Outlook by Application
7.7. North America Veterinary Infectious Disease Therapeutics Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Veterinary Infectious Disease Therapeutics Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Veterinary Infectious Disease Therapeutics Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Veterinary Infectious Disease Therapeutics Companies
CHAPTER 8- EUROPE VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Veterinary Infectious Disease Therapeutics Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Veterinary Infectious Disease Therapeutics Market Trends and Growth Opportunities to 2034
8.5. Europe Veterinary Infectious Disease Therapeutics Market Size Outlook by Type
8.6. Europe Veterinary Infectious Disease Therapeutics Market Size Outlook by Application
8.7. Europe Veterinary Infectious Disease Therapeutics Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Veterinary Infectious Disease Therapeutics Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Veterinary Infectious Disease Therapeutics Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Veterinary Infectious Disease Therapeutics Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Veterinary Infectious Disease Therapeutics Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Veterinary Infectious Disease Therapeutics Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Veterinary Infectious Disease Therapeutics Companies
CHAPTER 9- ASIA PACIFIC VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Veterinary Infectious Disease Therapeutics Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Veterinary Infectious Disease Therapeutics Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Veterinary Infectious Disease Therapeutics Market Size Outlook by Type
9.6. Asia Pacific Veterinary Infectious Disease Therapeutics Market Size Outlook by Application
9.7. Asia Pacific Veterinary Infectious Disease Therapeutics Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Veterinary Infectious Disease Therapeutics Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Veterinary Infectious Disease Therapeutics Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Veterinary Infectious Disease Therapeutics Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Veterinary Infectious Disease Therapeutics Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Veterinary Infectious Disease Therapeutics Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Veterinary Infectious Disease Therapeutics Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Veterinary Infectious Disease Therapeutics Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Veterinary Infectious Disease Therapeutics Market Trends and Growth Opportunities to 2034
10.5. South and Central America Veterinary Infectious Disease Therapeutics Market Size Outlook by Type
10.6. South and Central America Veterinary Infectious Disease Therapeutics Market Size Outlook by Application
10.7. South and Central America Veterinary Infectious Disease Therapeutics Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Veterinary Infectious Disease Therapeutics Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Veterinary Infectious Disease Therapeutics Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Veterinary Infectious Disease Therapeutics Companies
CHAPTER 11- MIDDLE EAST AND AFRICA VETERINARY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Veterinary Infectious Disease Therapeutics Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Veterinary Infectious Disease Therapeutics Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Veterinary Infectious Disease Therapeutics Market Size Outlook by Type
11.6. Middle East and Africa Veterinary Infectious Disease Therapeutics Market Size Outlook by Application
11.7. Middle East and Africa Veterinary Infectious Disease Therapeutics Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Veterinary Infectious Disease Therapeutics Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Veterinary Infectious Disease Therapeutics Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Veterinary Infectious Disease Therapeutics Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Veterinary Infectious Disease Therapeutics Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Veterinary Infectious Disease Therapeutics Industry
Zoetis Inc.
Merck & Co., Inc
Boehringer Ingelheim Animal Health
Elanco Animal Health Incorporated
Ceva Sant? Animale
Virbac S.A.
Vetoquinol S.A.
Dechra Pharmaceuticals PLC
IDEXX Laboratories, Inc.
Phibro Animal Health Corporation
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
